Tag Archives: NKTR

Top 5 Low Price Stocks To Buy Right Now

A few weeks ago, we published an article that characterized Gilead (GILD) as a “Value Trap.” That article was a follow-up to an earlier article which used our work on Gilead as an example of how a solid conceptual framework could help investors make better decisions. Both of these articles were based on a 16-page valuation report on Gilead we published to our members in September, 2016.

We caught a lot of flack for the recent characterization of Gilead as a value trap, but our opinion was redeemed on February 7th, when the stock fell heavily after a disappointing earnings announcement.

In today’s article, we’ll take another look at the valuation process – the most important weapon in an investor’s arsenal – in a continuation of the Gilead example. We would invite new readers to read through each of the earlier articles as well, to get a picture of the overall process!

Investing Anecdotes are Dangerous!

What interested us in September 2016, when we made our original analysis of Gilead, was the noise among the value investing community about what a deal Gilead was because the stock was trading at such a low Price-to-Earnings (P/E) ratio (See our article Three Things You Should Know About Gilead).

Top 5 Low Price Stocks To Buy Right Now: Diana Shipping inc.(DSX)

Advisors’ Opinion:

  • [By Joseph Griffin]

    Pangaea Logistics Solutions (NYSE: DSX) and Diana Shipping (NYSE:DSX) are both small-cap transportation companies, but which is the better investment? We will contrast the two companies based on the strength of their profitability, dividends, institutional ownership, earnings, risk, analyst recommendations and valuation.

  • [By Joseph Griffin]

    Get a free copy of the Zacks research report on Diana Shipping (DSX)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

  • [By Reuben Gregg Brewer]

    Over the past year, dry bulk vessel owner Diana Shipping Inc. (NYSE:DSX) has seen its stock fall around 3%. Meanwhile, shipping peer DryShips Inc.’s (NASDAQ:DRYS) stock has rocketed higher, more than doubling in price over the span. There are good reasons for that advance, but it doesn’t make DryShips the better investment option. Here’s why Diana Shipping is the better company if you are interested in the volatile shipping space.

  • [By Shane Hupp]

    Diana Shipping (NYSE: DSX) and Frontline (NYSE:FRO) are both small-cap transportation companies, but which is the superior investment? We will contrast the two businesses based on the strength of their profitability, risk, institutional ownership, valuation, dividends, earnings and analyst recommendations.

Top 5 Low Price Stocks To Buy Right Now: CHS Inc(CHSCL)

Advisors’ Opinion:

  • [By Joseph Griffin]

    CHS (NASDAQ:CHSCL) was upgraded by analysts at BidaskClub from a “strong sell” rating to a “sell” rating in a research report issued on Friday.

Top 5 Low Price Stocks To Buy Right Now: FS Bancorp, Inc.(FSBW)

Advisors’ Opinion:

  • [By Ethan Ryder]

    FS Bancorp (NASDAQ:FSBW) – Research analysts at FIG Partners boosted their Q2 2018 earnings estimates for FS Bancorp in a research report issued to clients and investors on Thursday, May 3rd. FIG Partners analyst T. Coffey now anticipates that the bank will post earnings per share of $1.16 for the quarter, up from their prior forecast of $1.13. FIG Partners also issued estimates for FS Bancorp’s FY2018 earnings at $4.70 EPS, Q1 2019 earnings at $1.08 EPS, Q4 2019 earnings at $1.33 EPS and FY2019 earnings at $5.09 EPS.

  • [By Ethan Ryder]

    Get a free copy of the Zacks research report on FS Bancorp (FSBW)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

  • [By Ethan Ryder]

    Get a free copy of the Zacks research report on FS Bancorp (FSBW)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

Top 5 Low Price Stocks To Buy Right Now: Sapiens International Corporation N.V.(SPNS)

Advisors’ Opinion:

  • [By Stephan Byrd]

    Shares of Sapiens International Co. (NASDAQ:SPNS) have earned a consensus rating of “Hold” from the six brokerages that are presently covering the firm, MarketBeat.com reports. One analyst has rated the stock with a sell rating, three have given a hold rating and two have assigned a buy rating to the company. The average 1-year price objective among brokers that have updated their coverage on the stock in the last year is $12.50.

  • [By Ethan Ryder]

    Get a free copy of the Zacks research report on Sapiens International (SPNS)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

  • [By Logan Wallace]

    Sapiens International Co. (NASDAQ:SPNS) – William Blair boosted their Q2 2018 earnings per share estimates for Sapiens International in a report issued on Tuesday, May 8th. William Blair analyst B. Suri now forecasts that the technology company will post earnings of $0.11 per share for the quarter, up from their prior forecast of $0.10. William Blair currently has a “Market Perform” rating on the stock. William Blair also issued estimates for Sapiens International’s FY2018 earnings at $0.47 EPS and FY2019 earnings at $0.54 EPS.

  • [By Shane Hupp]

    Sapiens International (NASDAQ:SPNS) issued its quarterly earnings results on Monday. The technology company reported $0.13 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.10 by $0.03, Briefing.com reports. Sapiens International had a net margin of 0.13% and a return on equity of 6.81%. The business had revenue of $71.09 million for the quarter, compared to analyst estimates of $67.68 million. During the same quarter in the prior year, the business posted $0.02 EPS. Sapiens International’s revenue for the quarter was up 25.8% compared to the same quarter last year.

  • [By Logan Wallace]

    Sapiens International (NASDAQ: SPNS) and NetSol Technologies (NASDAQ:NTWK) are both small-cap computer and technology companies, but which is the superior business? We will compare the two companies based on the strength of their analyst recommendations, profitability, valuation, institutional ownership, earnings, dividends and risk.

Top 5 Low Price Stocks To Buy Right Now: Nektar Therapeutics(NKTR)

Advisors’ Opinion:

  • [By Maxx Chatsko]

    Shares of Nektar Therapeutics (NASDAQ:NKTR) rose as much as 17% today as investors poured back into the biopharma stock following a sharp sell-off earlier this week. The huge drop days ago was caused by a disappointing weekend presentation at the American Society of Clinical Oncology’s annual meeting, in which the company shared preliminary data on an important ongoing program evaluating a combination of drug candidate NKTR-214 with Opdivo from Bristol-Myers Squibb to treat various solid tumor cancers.

  • [By Ethan Ryder]

    Eqis Capital Management Inc. trimmed its stake in Nektar Therapeutics (NASDAQ:NKTR) by 51.8% in the second quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 4,360 shares of the biopharmaceutical company’s stock after selling 4,679 shares during the period. Eqis Capital Management Inc.’s holdings in Nektar Therapeutics were worth $213,000 at the end of the most recent reporting period.

  • [By ]

    Another interesting candidate from the list is Nektar Therapeutics (Nasdaq: NKTR). The biopharmaceutical company has a handful of drug developments in the immuno-oncology marketplace with its lead candidate being NKTR-214 — a drug that stimulates a cancer patient’s own immune system to fight cancer.

Best Undervalued Stocks For 2018

The OPEC deal and two new pipelines to be built in Western Canada saw my favorite oil & gas stocks tick higher – much higher in some cases. And, this should be just the beginning!

As supply and demand come back into balance, Western Canadian producers should find prices sufficient to fund growth without adding to debt. At the same time, the Trans Mountain pipeline will provide access to tidewater and the upgraded Enbridge line will provide a bit more capacity, both of which should act to shrink the differential between Alberta prices and West Texas Intermediate, currently somewhere in the low-to-mid teens. Both projects are expected to be complete by 2019, easing major transportation bottlenecks.

A run-down of today’s action shows the leverage on the day of the announcement:

Penn West (NYSE:PWE) gained $0.17 per share or 10.8%

Pengrowth (NYSE:PGH) added $0.23 or 17.8%

Enerplus (NYSE:ERF) tacked on $1.29 or 17.5%

All three of these names remain undervalued in my opinion. All three have -made significant progress in de-levering their balance sheets (although PGH still has a way to go to be out of the woods entirely). All three expect to fund their capital outlays through internally generated cash flows and still reduce debt even further.

Best Undervalued Stocks For 2018: Nektar Therapeutics(NKTR)

Advisors’ Opinion:

  • [By Cory Renauer]

    Even though it’s been a rough few years for many of the industry’s larger players, some smaller upstarts have produced stunning gains lately. Shares ofNektar Therapeutics (NASDAQ:NKTR), BeiGene Ltd. (NASDAQ:BGNE), and AveXis Inc. (NASDAQ:AVXS) have risen at least 500% in less than three years.

  • [By Stephan Byrd]

    TRADEMARK VIOLATION NOTICE: “Nektar Therapeutics (NKTR) Trading Down 7%” was originally reported by Ticker Report and is the property of of Ticker Report. If you are reading this piece of content on another site, it was stolen and republished in violation of US & international trademark and copyright law. The original version of this piece of content can be viewed at www.tickerreport.com/banking-finance/3362849/nektar-therapeutics-nktr-trading-down-7.html.

  • [By Keith Speights]

    But some stocks don’t take nearly that long to double. Three stocks in particularhave doubled investors’ money — and more — in just the last 12 months. Here’s why Nektar Therapeutics (NASDAQ:NKTR), CRISPR Therapeutics (NASDAQ:CRSP), and Sarepta Therapeutics (NASDAQ:SRPT) became such huge winners — and whether or not their impressive momentum can continue.

Best Undervalued Stocks For 2018: Suncor Energy Inc.(SU)

Advisors’ Opinion:

  • [By Tyler Crowe, Reuben Gregg Brewer, and Travis Hoium]

    Clearly, investors should be at least looking at stocks in this industry, so we asked three of our investing contributors to each highlight a great company in the industry to help you get started. Here’s why they picked Baker Hughes, a GE Company (NYSE:BHGE), Suncor Energy (NYSE:SU), and Total (NYSE:TOT).

  • [By Tyler Crowe]

    I don’t know if you have noticed, but oil prices have been on the rise lately, which has done miraculous things for the bottom lines at oil and gas companies. The same can be said for Suncor Energy (NYSE:SU), which was able to post a rather healthy earnings per share number considering one of its major oil sands facilities was shut down in the most recent quarter.

  • [By Logan Wallace]

    Virginia Retirement Systems ET AL lifted its holdings in Suncor Energy (NYSE:SU) (TSE:SU) by 24.5% during the first quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 336,200 shares of the oil and gas producer’s stock after buying an additional 66,088 shares during the period. Virginia Retirement Systems ET AL’s holdings in Suncor Energy were worth $11,602,000 at the end of the most recent reporting period.

Best Undervalued Stocks For 2018: The Michaels Companies, Inc.(MIK)

Advisors’ Opinion:

  • [By ]

    The Michaels Companies (Nasdaq: MIK) owns six brands in the retail arts & crafts space, including the top specialty retailer in North America and the #1 wholesale distributor by market share. The arts & crafts segment should hold up well in any kind of consumer weakness as people look to save money by staying in and spending on inexpensive crafts.

Best Medical Stocks To Invest In Right Now

As top Republicans see it, a medical malpractice crisis is threatening U.S. health care: Frivolous lawsuits are driving up malpractice insurance premiums and forcing physicians out of business. Doctors and hospitals live in fear of litigation, ordering excessive tests and treatments that make health care unaffordable for Americans.

That’s why Republican House Speaker Paul Ryan and Rep. Tom Price, tapped to be the nation’s top health official by President-elect Donald Trump, are vowing to make tort reform a key part of their replacement plan for the Affordable Care Act.

But, according to researchers and industry experts, the reality doesn’t match the GOP rhetoric. They say the nation’s medical malpractice insurance industry is running smoothly and the last crisis dates back more than a decade.

“It’s a wonderful time for doctors looking for coverage and it’s never been better for insurers,” said Michael Matray, editor of Medical Liability Monitor, a trade publication.

Best Medical Stocks To Invest In Right Now: Jagged Peak Energy Inc. (JAG)

Advisors’ Opinion:

  • [By Logan Wallace]

    These are some of the media headlines that may have effected Accern’s scoring:

    Get Jagged Peak Energy alerts:

    Jagged Peak Energy (JAG) Raised to “Hold” at Zacks Investment Research (americanbankingnews.com) Jagged Peak Energy (JAG) Upgraded to “Hold” by ValuEngine (americanbankingnews.com) Jagged Peak Energy (JAG) Set to Announce Earnings on Thursday (americanbankingnews.com) Insider Selling: Jagged Peak Energy Inc (JAG) CFO Sells 50,000 Shares of Stock (americanbankingnews.com) Jagged Peak Energy Inc (JAG) Given Consensus Recommendation of “Hold” by Analysts (americanbankingnews.com)

    Jagged Peak Energy stock opened at $14.25 on Friday. The company has a current ratio of 0.35, a quick ratio of 0.35 and a debt-to-equity ratio of 0.22. Jagged Peak Energy has a 1-year low of $11.21 and a 1-year high of $16.55. The company has a market capitalization of $2,993.81, a P/E ratio of 54.81 and a beta of -1.13.

Best Medical Stocks To Invest In Right Now: Greenlight Capital Re Ltd.(GLRE)

Advisors’ Opinion:

  • [By Jim Robertson]

    Note that hedge fund mogul David Einhorn has been a director ofthe predecessor company since May 2006. Mr. Einhorn co-founded, and has served as the President of, Greenlight Capital, Inc., since January 1996. Funds managed by Greenlight are some ofthe Companys principal stockholders. Since July 2004, Mr. Einhorn has served as Chairman of the Board of Greenlight Capital Re, Ltd (Nasdaq: GLRE).

Best Medical Stocks To Invest In Right Now: NiSource, Inc(NI)

Advisors’ Opinion:

  • [By Ethan Ryder]

    Wedbush Securities Inc. raised its holdings in NiSource (NYSE:NI) by 25.3% during the 1st quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 13,858 shares of the utilities provider’s stock after acquiring an additional 2,800 shares during the period. Wedbush Securities Inc.’s holdings in NiSource were worth $331,000 at the end of the most recent reporting period.

  • [By Lisa Levin]

    In trading on Thursday, utilities shares fell by 2.01 percent. Meanwhile, top losers in the sector included Unitil Corporation (NYSE: UTL), down 9 percent, and NiSource Inc. (NYSE: NI), down 5 percent.

Best Medical Stocks To Invest In Right Now: Iteris, Inc.(ITI)

Advisors’ Opinion:

  • [By Lisa Levin]

    Gainers

    Pyxis Tankers Inc. (NYSE: PXS) rose 47.48 percent to $$5.56, after the company announced it has entered into a definitive securities purchase agreement with a group of investors, which will result in gross proceeds of $4.8 million.
    Sigma Designs Inc (NASDAQ: SIGM) rose 22.77 percent to $6.88. Silicon Laboratories (NASDAQ: SLAB) announced plans to buy Sigma Designs for $7.05 per share in cash.
    Steadymed Ltd (NASDAQ: STDY) rose 19.35 percent to $3.70, after the company reported that no clinical trials were required for Trevyent and that the FDA had agreed to the pathway for the drug candidate's NDA resubmission.
    Iteris, Inc. (NASDAQ: ITI) rose 15.73 percent to $7.06. Earlier in the week, Zacks Investment Research had upgraded the company from "Sell" to "Hold".
    Science Applications International Corp (NYSE: SAIC) rose 13.71 percent to $85.77 as the company reported better-than-expected earnings for its third quarter.
    Technical Communications Corporation (NASDAQ: TCCO) rose 12.41 percent to $6.07, after having risen sharply in pre-marketing trading.
    Radius Health, Inc. (NASDAQ: RDUS) rose 12.41 percent to $30.81 after the company provided an update on data from the Phase 1 005 clinical study of elacestrant in patients with estrogen receptor positive breast cancer during the 2017 San Antonio Breast Cancer Symposium.
    ForeScout Technologies, Inc. (NASDAQ: FSCT) rose 12.32 percent to $25.80 after the company reported its third quarter financial results.
    Prana Biotechnology Limited (NASDAQ: PRAN) rose 11.36 percent to $3.43, as the company announced a research collaboration with Takeda Pharmaceuticals to study the ability of movement disorders compound, PBT434 to slow or prevent neurodegeneration of the gastrointestinal system.
    Catalyst Biosciences, Inc. (NASDAQ: CBIO) rose 10.49 percent to $7.90 as the company announced the appointment of Arwa Shurrab and Jamie Ellen Siegel in its clinical hemophilia

Best Medical Stocks To Invest In Right Now: Nektar Therapeutics(NKTR)

Advisors’ Opinion:

  • [By Stephan Byrd]

    TRADEMARK VIOLATION NOTICE: “Nektar Therapeutics (NKTR) Trading Down 7%” was originally reported by Ticker Report and is the property of of Ticker Report. If you are reading this piece of content on another site, it was stolen and republished in violation of US & international trademark and copyright law. The original version of this piece of content can be viewed at www.tickerreport.com/banking-finance/3362849/nektar-therapeutics-nktr-trading-down-7.html.

  • [By Cory Renauer]

    Even though it’s been a rough few years for many of the industry’s larger players, some smaller upstarts have produced stunning gains lately. Shares ofNektar Therapeutics (NASDAQ:NKTR), BeiGene Ltd. (NASDAQ:BGNE), and AveXis Inc. (NASDAQ:AVXS) have risen at least 500% in less than three years.

  • [By Lisa Levin]

    Shares of Nektar Therapeutics (NASDAQ: NKTR) got a boost, shooting up 38 percent to $21.33 after the company reported that it has met its primary and secondary endpoints in Phase 3 Summit-07 study for chronic pain.

  • [By Sean Williams]

    Shares of Nektar Therapeutics (NASDAQ:NKTR), a biopharmaceutical company that utilizes its proprietary intellectual property via licensing deals and through collaborations in the clinical development process to help fight cancer, autoimmune diseases, and chronic pain, surged as much as 20% on Thursday after the company reported its fourth-quarter and full-year results after the closing bell on Wednesday.

Best Medical Stocks To Invest In Right Now: Diana Shipping inc.(DSX)

Advisors’ Opinion:

  • [By Dan Caplinger]

    Despite a lack of conviction in the market at large, some stocks posted sharp gains on Friday, and Diana Shipping (NYSE:DSX), Akorn (NASDAQ:AKRX), and Granite Construction (NYSE:GVA) were among the best performers on the day. Below, we’ll look more closely at these stocks to tell you why they did so well.

  • [By Jim Robertson]

    On Thursday, our Under the Radar Moversnewsletter suggested small cap dry bulk shippingDiana Shipping Inc (NYSE: DSX) as a short/bearish position:

  • [By Dan Caplinger]

    The stock market had a negative tone on Wednesday, although major benchmarks moved in different directions. The Dow Jones Industrials took the biggest hit, falling triple digits as one of its most influential components suffered an earnings-related drop. Relative strength in the Nasdaq Composite showed cross-currents in the overall market, but several individual stocks had substantial declines for the day, andRite Aid (NYSE:RAD), Diana Shipping (NYSE:DSX), and Finisar (NASDAQ:FNSR) were among the worst performers. Below, we’ll look more closely at these stocks to tell you why they did so poorly.

Top 5 Bank Stocks To Own Right Now

The federal government and Wall Street are at it again, scratching each other’s backs at your expense…

They did it in 1999, when the government repealed Glass-Steagall – and opened the door leading to the Financial Crisis.

They did it in September 2008, when the Treasury Department loaned Wall Street banks $700 billion of U.S. taxpayer money to bail them out from their own misdeeds, many of which stemmed from repealing Glass-Steagall.

Blackstone Group CEO Tony James

And yet again in 2010 when they passed Dodd-Frank, a reform that was meant to reign in excesses but which has actually further concentrated Wall Street’s grip.

And now these two institutions are pushing to socialize your retirement savings accounts…

Top 5 Bank Stocks To Own Right Now: Pacira Pharmaceuticals, Inc.(PCRX)

Advisors’ Opinion:

  • [By Jon C. Ogg]

    Pacira Pharmaceuticals, Inc. (NASDAQ: PCRX) has found itself in the middle of a great opportunity but not being able to make the last mile of the race. Unfortunately, pain management in a non-opioid treatment has become an elusive target. And it’s too bad when you consider how many people have become addicted to opioids in America.

  • [By Lisa Levin]

    Pacira Pharmaceuticals Inc (NASDAQ: PCRX) shares were also up, gaining 17 percent to $39.80. Pacira Pharmaceuticals reported preliminary 2016 revenue of $276.4 million.

  • [By Chris Lange]

    Pacira Pharmaceuticals Inc. (NASDAQ: PCRX) has announced preliminary unaudited total revenues and net product sales for Exparel for the fourth quarter and the full year. Total revenues were $72.9 million and $276.4 million for the fourth quarter and full year, respectively. Exparel net product sales were $71.4 million and $239.9 million for the same periods, respectively. The consensus estimates from Thomson Reuters were calling for revenues of $72.56 million in the fourth quarter and $276.09 million in the full year.

Top 5 Bank Stocks To Own Right Now: Nektar Therapeutics(NKTR)

Advisors’ Opinion:

  • [By Sean Williams]

    Shares of Nektar Therapeutics (NASDAQ:NKTR), a biopharmaceutical company that utilizes its proprietary intellectual property via licensing deals and through collaborations in the clinical development process to help fight cancer, autoimmune diseases, and chronic pain, surged as much as 20% on Thursday after the company reported its fourth-quarter and full-year results after the closing bell on Wednesday.

  • [By Lisa Levin]

    Shares of Nektar Therapeutics (NASDAQ: NKTR) got a boost, shooting up 38 percent to $21.33 after the company reported that it has met its primary and secondary endpoints in Phase 3 Summit-07 study for chronic pain.

  • [By Ben Levisohn]

    Nektar Therapeutics (NKTR) has soared 21% to $18.80 after positive results from a pain-killer trial.

    Tiffany (TIF) has gained 1.6% to $93.90 after getting upgraded to Outperform from Market Perform at William Blair.

  • [By Todd Campbell]

    Nektar Therapeutics (NASDAQ:NKTR) is an intriguing commercial-stage biotech company that’s just reported positive late-stage trial results for its pain-busting drug NKTR-181. However, shares have jumped on the news, and the company’s market cap has swollen to more than $3 billion. Is there more running room left for its investors?

Top 5 Bank Stocks To Own Right Now: Tobira Therapeutics, Inc.(TBRA)

Advisors’ Opinion:

  • [By Benzinga News Desk]

    Allergan (NYSE: AGN) acquired Akarna Therapeutics global rights to AKN-083 for up-front payment of $50 million. This came just hours after Allergan bought Tobira Therapeutics (NASDAQ: TBRA) for upfront Payment of $28.35 share in cash, up to $49.84 per share in CVRs.

Top 5 Bank Stocks To Own Right Now: Firsthand Technology Value Fund, Inc.(SVVC)

Advisors’ Opinion:

  • [By Hibah Yousuf]

    Similarly, Twitter is also the biggest holding in the Firsthand Technology Value Fund (SVVC). With just over 1 million shares of the social media platform, Twitter represents nearly 11% of the total portfolio as of mid-year. Shares of Firsthand Technology Value jumped more than 6% Friday.

Top 5 Bank Stocks To Own Right Now: NeuroMetrix Inc.(NURO)

Advisors’ Opinion:

  • [By WWW.MONEYSHOW.COM]

    NeuroMetrix (NURO) makes and markets wearable neuro-stimulation therapeutic devices. Cash per share is $1.37, with the stock selling more than 20% below that.